Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Alison J. Moskowitz, Joachim Yahalom, Tarun Kewalramani, Jocelyn C. Maragulia, Jill M. Vanak, Andrew D. Zelenetz, Craig H. Moskowitz

Blood (2010) 116 (23): 4934–4937.

https://doi.org/10.1182/blood-2010-05-282756

Published: 2010

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Journal Articles

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.

Alison J. Moskowitz, MD, Paul A. Hamlin, Jr., MD, John Gerecitano, MD, PhD, Steven M. Horwitz, MD, Matthew Matasar, MD, Jessica Meikle, Ariela Noy, MD, Maria Lia Palomba, MD, Carol S. Portlock, MD, David J. Straus, MD, Jill M Vanak, ACNP, Andrew D. Zelenetz, MD, PhD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 720.

https://doi.org/10.1182/blood.V114.22.720.720

Published: 2009

Journal Articles

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Craig H. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Paul A. Hamlin, Jr., MD, Steven M. Horwitz, MD, Ariela Noy, MD, Carol S. Portlock, MD, David J. Straus, MD, John Gerecitano, MD, PhD, Tarun Kewalramani, MD, Jill M. Vanak, ACNP, Jocelyn C. Maragulia, Joachim Yahalom, MD

Blood (2008) 112 (11): 775.

https://doi.org/10.1182/blood.V112.11.775.775

Published: 2008

Journal Articles

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Alison J. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Tarun Kewalramani, MD, Jill M Vanak, ACNP, Jocelyn c Maragulia, Joachim Yahalom, MD, Craig Moskowitz, MD

Blood (2008) 112 (11): 776.

https://doi.org/10.1182/blood.V112.11.776.776

Published: 2008

NARROW

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only